Note: This story was updated June 7, 2022, to note that CENTAUR is a Phase 2, not Phase 2/3, trial and that AMX0035 reduced the risk of death by 43%, instead of 44%. There also has been no indication that U.S. sites will open soon for the PHOENIX trial.

Lisa Cross thought having amyotrophic lateral sclerosis (ALS) meant she would have to give up on acting and the theater. A longtime stage actor, Cross, 66, had worked in just about every aspect of the entertainment industry: she was a dancer and singer; a director, choreographer, and teacher; an…

Eledon Pharmaceuticals’ investigational antibody-based therapy, tegoprubart, safely and effectively reduces levels of inflammatory biomarkers in adults with amyotrophic lateral sclerosis (ALS), according to top-line data from a Phase 2a clinical trial. Exploratory findings suggested that lower levels of inflammatory biomarkers and whether tegoprubart’s target is significantly reduced,…

Major league baseball teams are poised to mark Lou Gehrig Day, set aside to honor the legendary New York Yankees first baseman whose career was cut short amyotrophic lateral sclerosis (ALS), the progressive neurodegenerative disorder that after his death in 1941 became known as “Lou Gehrig’s Disease.” In addition to…

Health Canada has started to review AB Science’s application requesting that masitinib be approved as an add-on therapy for amyotrophic lateral sclerosis (ALS). The application will be reviewed under the notice of compliance with conditions (NOC/c) policy, agreed upon with the agency in February. This policy allows early…

Stanley H. Appel, a world-renowned expert in amyotrophic lateral sclerosis (ALS) and the founder of the first multidisciplinary clinic dedicated to ALS care and research in the U.S., will receive the Tribute Award from the Muscular Dystrophy Association (MDA). The award acknowledges the neurologist’s work in pioneering ALS…

The rarity of amyotrophic lateral sclerosis (ALS) in children makes it impossible to realistically conduct clinical trials of experimental medicines in this population, researchers across Europe argue in a paper. “Given the absence of consensus on pediatric ALS as a disease entity, the extremely low prevalence of ALS in…

After a two-year hiatus, the Muscular Dystrophy Association (MDA) is bringing back its in-person Wings Over Wall Street fundraiser gala in New York City, with proceeds going to support MDA research into promising amyotrophic lateral sclerosis (ALS) treatments. The June 9 event, starting at 6 p.m. EST at…

The Barrow Neurological Institute in Phoenix, Arizona, is calling on people with amyotrophic lateral sclerosis (ALS) and their family members and friends to participate in a biomarker study that aims to create a bank of biological samples and clinical data collected over time. Data will be made available…

One-time delivery of a CRISPR-based gene therapy significantly reduced the buildup of toxic RNA molecules resulting from C9ORF72 mutations in cells and mouse models of amyotrophic lateral sclerosis (ALS), the therapy’s developer, Locanabio, reported. The approach was designed using the company’s CORRECTx platform, which uses CRISPR technology to…